Shionogi Of Japan Plans U.S. Focus On Metabolic Syndrome
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi acquired U.S.-based Sciele Pharma last year to give the Japanese firm a way to market its metabolic syndrome products, Shionogi President Isao Teshirogi says. He said his company wants to move away from its focus on antibiotics and give more emphasis to its medicines such as Crestor (rosuvastatin), marketed by AstraZeneca outside of Japan. Although Shionogi expects to continue to rely on Crestor as a major revenue source, the company faces a need for other sources of profit when the drug loses patent protection beginning in 2016. Teshirogi said the Sciele acquisition gives Shionogi a chance to use the U.S. firm's 800 medical representatives to sell an obesity drug it is developing. (Click here for more - a subscription may be required
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.